Mark Vishnepolsky is a Nephrology physician. OpenAlex indexes 9 publications with 377 citations (h-index 3).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1294 S Jones Blvd
Las Vegas, NV 89146
Telephone
702-877-1887Provider last certified this registry record 24 Jan 2024.
Industry payments
20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Otsuka America Pharmaceutical, Inc.Program year202516 payments$13,627openpaymentsdata.cms.gov ↗
- Calliditas Therapeutics US Inc.Program year20251 payment
- Novartis Pharmaceuticals CorporationProgram year202510 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
51.9%Calcium channel blocker11.5%Amlodipine Besylate57%Nifedipine Er43%Part D≥33 patientsAngiotensin receptor blocker (ARB)10.1%Losartan Potassium62%Telmisartan38%Part D≥36 patients+ 10 more classes in this area
Metabolism & gastrointestinal
23.2%Vitamin D3 Analog9.5%Calcitriol91%Rayaldee10%Part D<11 patientsGLP-1 receptor agonist4.5%Mounjaro58%Ozempic42%Part D<11 patients+ 4 more classes in this area
Other
14.3%Phosphate Binder7.7%Sevelamer Carbonate100%Part D≥31 patientsDrugs for treatment of hyperkalemia and hyperphosphatemia6.6%Lokelma40%Auryxia33%Velphoro28%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- WCN25-778 AFFINITY study: 1-year results of atrasentan in IgA nephropathy (IgAN)
Kidney International Reports
2025 - Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial
Repository@Nottingham (University of Nottingham)
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”